G Stojan1, M Petri1. 1. Division of Rheumatology, Johns Hopkins University School of Medicine, Key Indexing Terms: systemic lupus erythematosus, glucocorticoid.
Abstract
PURPOSE OF REVIEW: Glucocorticoids have been the mainstay of treatment in systemic lupus erythematosus for more than half a century. Despite advancements in knowledge concerning the pathophysiology of systemic lupus, the genomic/non-genomic actions of glucocorticoids, and the use of novel therapeutic agents in SLE, the burden of toxicity from glucocorticoid use remains unchanged. RECENT FINDINGS: SLE patients receiving long-term prednisone therapy are at significant risk of morbidity due to permanent organ damage and prednisone daily dosages above 6 mg have been shown to increase the risk of future organ damage by 50%. Glucocorticoid use carries a higher risk of opportunistic infections, iatrogenic osteoporosis and avascular necrosis, an increase in risk of cardiovascular events, cataracts and glaucoma, as well as psychiatric adverse effects like psychosis and manic episodes. There are limited data regarding the relative efficacy of the different glucocorticoid formulations or dosing regimens. SUMMARY: The use and dosing of glucocorticoids in SLE remains more art than science, although our knowledge regarding their complex genomic and non-genomic effects, as well as the resultant adverse effects, has greatly expanded over the past half a century.
PURPOSE OF REVIEW: Glucocorticoids have been the mainstay of treatment in systemic lupus erythematosus for more than half a century. Despite advancements in knowledge concerning the pathophysiology of systemic lupus, the genomic/non-genomic actions of glucocorticoids, and the use of novel therapeutic agents in SLE, the burden of toxicity from glucocorticoid use remains unchanged. RECENT FINDINGS:SLEpatients receiving long-term prednisone therapy are at significant risk of morbidity due to permanent organ damage and prednisone daily dosages above 6 mg have been shown to increase the risk of future organ damage by 50%. Glucocorticoid use carries a higher risk of opportunistic infections, iatrogenic osteoporosis and avascular necrosis, an increase in risk of cardiovascular events, cataracts and glaucoma, as well as psychiatric adverse effects like psychosis and manic episodes. There are limited data regarding the relative efficacy of the different glucocorticoid formulations or dosing regimens. SUMMARY: The use and dosing of glucocorticoids in SLE remains more art than science, although our knowledge regarding their complex genomic and non-genomic effects, as well as the resultant adverse effects, has greatly expanded over the past half a century.
Authors: C M Spies; D H S Schaumann; T Berki; K Mayer; M Jakstadt; D Huscher; C Wunder; G-R Burmester; A Radbruch; R Lauster; A Scheffold; F Buttgereit Journal: Ann Rheum Dis Date: 2006-01-31 Impact factor: 19.103
Authors: H Yokoyama; T Takabatake; M Takaeda; T Wada; T Naito; K Ikeda; S Goshima; K Takasawa; N Tomosugi; K Kobayashi Journal: Kidney Int Date: 1992-09 Impact factor: 10.612
Authors: Celline C Almeida-Brasil; John G Hanly; Murray Urowitz; Ann Elaine Clarke; Guillermo Ruiz-Irastorza; Caroline Gordon; Rosalind Ramsey-Goldman; Michelle Petri; Ellen M Ginzler; D J Wallace; Sang-Cheol Bae; Juanita Romero-Diaz; Mary Anne Dooley; Christine Peschken; David Isenberg; Anisur Rahman; Susan Manzi; Søren Jacobsen; Sam Lim; Ronald F van Vollenhoven; Ola Nived; Andreas Jönsen; Diane L Kamen; Cynthia Aranow; Jorge Sanchez-Guerrero; Dafna D Gladman; Paul R Fortin; Graciela S Alarcón; Joan T Merrill; Kenneth Kalunian; Manuel Ramos-Casals; Kristján Steinsson; Asad Zoma; Anca Askanase; Munther A Khamashta; Ian N Bruce; Murat Inanc; Michal Abrahamowicz; Sasha Bernatsky Journal: Ann Rheum Dis Date: 2021-12-15 Impact factor: 27.973